• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

针对肺癌中的血管内皮生长因子。

Targeting VEGF in lung cancer.

机构信息

Stanford University, Stanford Cancer Center, CA, USA.

出版信息

Expert Opin Ther Targets. 2012 Apr;16(4):395-406. doi: 10.1517/14728222.2012.669752. Epub 2012 Mar 23.

DOI:10.1517/14728222.2012.669752
PMID:22439677
Abstract

INTRODUCTION

VEGF promotes tumor angiogenesis and is an important target in various malignancies, including NSCLC.

AREAS COVERED

Here, the authors review the data that led to the approval of bevacizumab, a monoclonal antibody against VEGF, in the treatment of lung cancer. The authors also review the key results from a number of Phase II and Phase III trials involving other anti-angiogenic agents being studied in NSCLC, including small-molecule tyrosine kinase inhibitors against the VEGF-receptor and vascular-disrupting agents (VDAs).

EXPERT OPINION

Results from ongoing studies and the identification of reliable biomarkers remain critical goals in understanding the exact role of these anti-angiogenic agents in the treatment paradigm of NSCLC.

摘要

简介

VEGF 促进肿瘤血管生成，是包括 NSCLC 在内的多种恶性肿瘤的重要靶点。

涵盖领域

本文作者回顾了贝伐珠单抗（一种针对 VEGF 的单克隆抗体）获批用于治疗肺癌的相关数据。作者还回顾了多项涉及 NSCLC 中其他抗血管生成药物的 II 期和 III 期试验的关键结果，这些药物包括针对 VEGF 受体的小分子酪氨酸激酶抑制剂和血管破坏剂（VDAs）。

专家意见

了解这些抗血管生成药物在 NSCLC 治疗模式中的确切作用，关键仍在于对正在进行的研究结果和可靠生物标志物的识别。

相似文献

1
Targeting VEGF in lung cancer.针对肺癌中的血管内皮生长因子。
Expert Opin Ther Targets. 2012 Apr;16(4):395-406. doi: 10.1517/14728222.2012.669752. Epub 2012 Mar 23.
2
Targeting tumor neovasculature in non-small-cell lung cancer.靶向非小细胞肺癌中的肿瘤新生血管。
Crit Rev Oncol Hematol. 2013 May;86(2):130-42. doi: 10.1016/j.critrevonc.2012.10.003. Epub 2012 Nov 15.
3
Angiogenesis inhibitors in the treatment of lung cancer.血管生成抑制剂在肺癌治疗中的应用
Crit Rev Oncol Hematol. 2007 May;62(2):93-104. doi: 10.1016/j.critrevonc.2007.01.002. Epub 2007 Feb 15.
4
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.血管内皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌中的应用。
Clin Lung Cancer. 2010 Sep 1;11(5):311-9. doi: 10.3816/CLC.2010.n.039.
5
The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.血管内皮生长因子受体酪氨酸激酶抑制剂的新作用
Semin Oncol. 2005 Dec;32(6 Suppl 10):S23-9. doi: 10.1053/j.seminoncol.2005.10.005.
6
[Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].[胸部肿瘤学中的抗血管生成因子：成功、失败与前景]
Rev Mal Respir. 2011 Dec;28(10):1216-29. doi: 10.1016/j.rmr.2011.04.014. Epub 2011 Nov 4.
7
Angiogenesis inhibition in the treatment of lung cancer.血管生成抑制在肺癌治疗中的应用
Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 23):1-10; quiz 11-2.
8
[Anti-angiogenic agents in the treatment of lung cancer: indications and toxicities].[抗血管生成药物在肺癌治疗中的应用：适应证与毒性]
Rev Mal Respir. 2012 Feb;29(2):161-77. doi: 10.1016/j.rmr.2011.06.017. Epub 2012 Jan 4.
9
Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.靶向VEGF通路：非小细胞肺癌治疗中的抗血管生成策略
Crit Rev Oncol Hematol. 2008 Dec;68(3):183-96. doi: 10.1016/j.critrevonc.2008.05.002. Epub 2008 Jul 7.
10
Anti-angiogenic treatment of gastrointestinal malignancies.胃肠道恶性肿瘤的抗血管生成治疗
Cancer Invest. 2005;23(8):712-26. doi: 10.1080/07357900500360024.

引用本文的文献

1
The interaction of platelet-related factors with tumor cells promotes tumor metastasis.血小板相关因子与肿瘤细胞的相互作用促进了肿瘤转移。
J Transl Med. 2024 Apr 18;22(1):371. doi: 10.1186/s12967-024-05126-6.
2
VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment.VEGF/VEGFR 靶向治疗与非小细胞肺癌的免疫治疗：靶向肿瘤微环境。
Int J Biol Sci. 2022 May 29;18(9):3845-3858. doi: 10.7150/ijbs.70958. eCollection 2022.
3
Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01).
鳞状非小细胞肺癌患者潜在的抗血管生成治疗适宜性：EPISQUAMAB研究（GFPC 2015-01）
Cancer Manag Res. 2019 Dec 27;11:10821-10826. doi: 10.2147/CMAR.S219984. eCollection 2019.
4
Cytochalasin H Inhibits Angiogenesis the Suppression of HIF-1α Protein Accumulation and VEGF Expression through PI3K/AKT/P70S6K and ERK1/2 Signaling Pathways in Non-Small Cell Lung Cancer Cells.细胞松弛素H通过PI3K/AKT/P70S6K和ERK1/2信号通路抑制非小细胞肺癌细胞中的血管生成、HIF-1α蛋白积累和VEGF表达。
J Cancer. 2019 May 12;10(9):1997-2005. doi: 10.7150/jca.29933. eCollection 2019.
5
Isolation and characterization of three new anti-proliferative Sesquiterpenes from Polygonum barbatum and their mechanism via apoptotic pathway.从虎杖中分离并鉴定三种新型的具有抗增殖活性的倍半萜及其通过凋亡途径的作用机制。
BMC Cancer. 2017 Oct 23;17(1):694. doi: 10.1186/s12885-017-3667-9.
6
Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion.紫杉醇与阿瓦斯丁联合使用可增强对非小细胞肺癌恶性胸腔积液患者的治疗效果。
Medicine (Baltimore). 2016 Nov;95(47):e5392. doi: 10.1097/MD.0000000000005392.
7
Bronchial Artery Angiogenesis Drives Lung Tumor Growth.支气管动脉血管生成驱动肺肿瘤生长。
Cancer Res. 2016 Oct 15;76(20):5962-5969. doi: 10.1158/0008-5472.CAN-16-1131. Epub 2016 Aug 28.
8
Loss of the endothelial glycocalyx is associated with increased E-selectin mediated adhesion of lung tumour cells to the brain microvascular endothelium.内皮糖萼的丧失与E-选择素介导的肺肿瘤细胞与脑微血管内皮细胞黏附增加有关。
J Exp Clin Cancer Res. 2015 Sep 25;34:105. doi: 10.1186/s13046-015-0223-9.
9
Potential anti-cancer effect of curcumin in human lung squamous cell carcinoma.姜黄素对人肺鳞癌细胞的潜在抗癌作用。
Thorac Cancer. 2015 Jul;6(4):508-16. doi: 10.1111/1759-7714.12222. Epub 2015 Jan 26.
10
Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.化疗或酪氨酸激酶抑制剂联合贝伐单抗与单纯化疗或酪氨酸激酶抑制剂治疗非小细胞肺癌的疗效和安全性：一项系统评价和荟萃分析
Med Oncol. 2015 Feb;32(2):473. doi: 10.1007/s12032-014-0473-y. Epub 2015 Jan 21.